The 45th annual congress of the SEBBM (Spanish Society of Biochemistry and Molecular Biology) has recently taken place in Zaragoza. During the congress, young and experienced researchers shared knowledge and enjoyed a wide range of Plenary Lectures, Symposia, including the Hispanic-Portuguese scientific symposium and the education symposium, Meetings of the Scientific Groups of the SEBBM, Poster Sessions, and the Trade Exhibition of collaborating companies.
DIVERSA commits to the professional development of young researchers
DIVERSA strongly supports young talent. We believe in people. We have participated in the Professional Development Forum for young researchers by sharing our expertise and providing tips on how to engage with the entrepreneurship sector and the pharma and biotechnology industries.
DIVERSA has also fostered a Symposium to highlight the huge potential that nanotechnology has in the development of novel diagnostic and therapeutic tools.
Jesús Martínez de la Fuente, María de la Fuente, and Álvaro Somoza discussing nanotechnology’s potential in the development of novel diagnostic and therapeutic tools.
Our CEO/CSO, María de la Fuente, was accompanied by two recognized researchers that are responsible of the first-in-human clinical trial with magnetic nanoparticles for pancreatic cancer, Dr. Álvaro Somoza and for innovative and highly sensitive diagnostic techniques that can revolutionize the diagnosis of respiratory diseases and other diseases like cancer, as well as enhance patient monitoring, Dr. Jesús Martínez de la Fuente.
Álvaro Somoza, María de la Fuente, and Jesús Martínez de la Fuente during the Symposium fostered by DIVERSA.
Nanomedicine can be accessible to all
Access to nanotechnology to explore mechanistic aspects of new molecules and discover new therapeutic molecules and biomolecules has now been leveraged thanks to DIVERSA.
DIVERSA’s nanosystems can be acquired in the format of a lab reagent, to enhance intracellular delivery of drugs and biomolecules.
Apart from discovering new therapeutic approaches, DIVERSA’s nanosystems can promote the delivery of proteins, genes, and fluorophores, improving times and efficiencies of in vitro assays.
Standing out from competitors, DIVERSA’s nanosystems can be formulated by simply patenting, and adapted to in vivo delivery in disease models.
Lipid nanosystems outperform other alternatives
Of all nanoparticles approved for clinical use, lipid nanosystems are the most widely represented category. From liposomes to lipid nanoparticles, they are safe-by-design, scalable, reproducible, and can interact with cells without damaging their structures.
María de la Fuente has participated as an invited speaker to share the last trends in the joint session of the 63rd edition of the International Conference on the Bioscience of Lipids (ICBL) and the 3rd edition of the International Workshop on Translational Cancer Research (IWTCR), held in Palma de Mallorca (Spain).
María de la Fuente sharing DIVERSA’s science at the 63rd edition of the International Conference on the Bioscience of Lipids (ICBL).
Sharing and learning from experts in lipids, lipidomics, and cancer will impact the science behind DIVERSA.
We are focusing on products that exploit the advantages of our technology for delivering potent and efficient gene therapies and therapeutic peptides. The ultimate ambition is to improve patients’ lives. We aim to facilitate the translation of molecules into medicines, bridging the gap between molecules and patients.
All the knowledge gathered by developing our R&D portfolio translates into critical know-how and information that enriches DIVERSA’s reagents portfolio and increases the value of our co-development services.
